DARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma
(WorldNews Health)

· First Phase 3 study showing addition of the CD38-directed antibody DARZALEX® to carfilzomib in combination with dexamethasone · Data selected as a Late-Breaking Abstract at ASH 2019 ORLANDO, Fla., December 10, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 3 CANDOR study showing the addition of DARZALEX® (daratumumab) to carfilzomib (Kyprolis®) and dexamethasone (DKd), compared to carfilzomib and dexamethasone (Kd) alone, significantly improved progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma, resulting in a 37 percent reduction in the risk of progression or death (HR, 0.63; 95 percent CI,...